Charles Bennett to Policy Making
This is a "connection" page, showing publications Charles Bennett has written about Policy Making.
Connection Strength
0.569
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.175
-
Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin Hematol. 1999 Jan; 36(1 Suppl 2):26-9.
Score: 0.153
-
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. J Clin Oncol. 2016 12 20; 34(36):4320-4322.
Score: 0.132
-
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. Cancer Invest. 2000; 18(3):261-8.
Score: 0.041
-
Cancer insurance policies in Japan and the United States. West J Med. 1998 Jan; 168(1):17-22.
Score: 0.036
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
Score: 0.032